West Pharmaceutical Services, Inc. — Form 10-Q Summary
Reporting period: Three months ended March 31, 2012, compared with the three months ended March 31, 2011. The interim financial statements are unaudited and prepared under U.S. GAAP.
Business context
West develops and manufactures pharmaceutical packaging components and drug-delivery systems. Its reportable segments are Pharmaceutical Packaging Systems and Pharmaceutical Delivery Systems. Packaging Systems serves injectable-drug applications, while Delivery Systems provides safety, administration, proprietary drug-delivery and contract-manufacturing solutions.
Financial performance and key metrics
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Net sales | $316.3 million | $295.4 million | +7.1% |
| Gross profit | $101.1 million | $88.0 million | +14.8% |
| Gross margin | 31.9% | 29.8% | +2.1 percentage points |
| Operating profit | $41.7 million | $28.8 million | +44.8% |
| Operating margin | 13.2% | 9.7% | +3.5 percentage points |
| Net income | $29.2 million | $19.6 million | +49.0% |
| Net margin | 9.2% | 6.6% | +2.6 percentage points |
| Diluted earnings per share | $0.81 | $0.56 | +44.6% |
| Dividends declared per share | $0.18 | $0.17 | +5.9% |
Packaging Systems sales increased 9.2% to $235.7 million, while Delivery Systems sales increased 0.3% to $80.7 million. Packaging Systems operating profit rose 27.6% to $53.6 million; Delivery Systems operating profit rose 27.8% to $2.3 million.
Net cash provided by operating activities was $13.8 million, compared with $9.5 million in the prior-year quarter. Capital expenditures were $32.4 million versus $19.4 million, resulting in net cash used in investing activities of $31.9 million. Net cash provided by financing activities was $24.2 million, primarily reflecting $29.3 million of net revolving-credit borrowings and $6.1 million of dividend payments.
Cash and cash equivalents were $100.2 million at March 31, 2012, supplemented by $26.4 million of short-term investments. Working capital was $200.4 million. Total debt was $381.4 million, including $86.5 million classified as current and $294.9 million of long-term debt. Net debt-to-total invested capital was 28.8%, compared with 28.2% at December 31, 2011. The company reported compliance with all debt covenants.
Material changes versus the prior comparable period
- Sales growth was driven primarily by broad-based pharmaceutical packaging demand, favorable product mix, modest volume increases and pricing actions.
- Excluding currency translation, consolidated sales increased 9.1%; reported sales were reduced by an unfavorable $6.0 million foreign-exchange effect.
- Gross margin benefited from product mix, volume and pricing, partly offset by higher raw-material, wage and benefit costs.
- Restructuring and other items improved from $1.7 million of expense to a $0.2 million benefit. R&D expense increased 20.3% to $8.3 million, principally for SmartDose and Crystal Zenith development.
- Interest expense, net declined 13.3% to $3.9 million, while the effective tax rate increased to 26.1% from 24.9%.
- Total debt increased $32.0 million from year-end, primarily due to $29.3 million of net revolving-credit borrowings and foreign-exchange effects.
- The company contributed $17.2 million to its U.S. qualified pension plan during the quarter.
Guidance, outlook, risks and unusual items
The filing does not provide specific full-year revenue, earnings or EPS guidance. Management stated that it believes available liquidity is sufficient for operating needs, product development, capital expansion, pension obligations and dividends. Capital projects included a new corporate office and research building, expected to be completed in late 2012 or early 2013, and a new compression-molding plant in China, expected to be completed in late 2012.
Management expected approximately $1.6 million of additional restructuring charges during the remainder of 2012, including approximately $1.2 million of cash costs and $0.4 million of non-cash charges. The company also recorded a $0.2 million increase in contingent consideration related to the SmartDose technology acquisition.
On April 27, 2012, after quarter-end, West entered into a new senior unsecured multi-currency revolving credit facility. The agreement provides $300.0 million of committed capacity, an accordion feature permitting expansion to $350.0 million with bank approval, and expires in April 2017. This replaced the prior $225.0 million facility.
Principal risks include demand fluctuations, customer inventory changes, competition and pricing pressure, regulatory approval and commercialization of customer products incorporating West systems, reliance on suppliers and partners including Daikyo, raw-material and petroleum-related cost inflation, foreign-exchange movements, supply-chain interruptions, execution of the restructuring plan, and the development and regulatory approval of new products. No material changes to previously disclosed legal proceedings or risk factors were reported.
The company uses interest-rate, foreign-currency and other hedges. It had a forward-start interest-rate swap for an anticipated $43.0 million term loan associated with the new corporate facility and reported foreign-currency exposure on international operations and debt.
Investor verification points
- Verify whether the strong Q1 margin improvement was sustained and how much reflected mix, pricing, restructuring benefits or other non-recurring items.
- Assess the effect of higher capital spending, pension contributions, working-capital requirements and additional restructuring costs on full-year free cash flow.
- Review the maturity and refinancing requirements for the $50.0 million Series A notes due in 2012 and the €20.4 million Euro Note A due in February 2013.
- Monitor leverage and interest-coverage compliance under the new credit agreement and the impact of variable interest rates.
- Evaluate demand, regulatory approval and commercialization milestones for SmartDose, Crystal Zenith, eris, ConfiDose and NovaGuard products.
- Track foreign-exchange effects, raw-material inflation and the company’s ability to implement pricing actions.
- Confirm the timing and final cost of the new corporate office and research building and the China manufacturing facility.